Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. trimmed its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 3.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,352,599 shares of the company's stock after selling 72,474 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 2.78% of Verve Therapeutics worth $13,269,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of Verve Therapeutics by 139.8% in the 3rd quarter. Barclays PLC now owns 222,919 shares of the company's stock valued at $1,079,000 after acquiring an additional 129,944 shares during the period. Geode Capital Management LLC increased its stake in Verve Therapeutics by 2.6% in the third quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company's stock valued at $7,749,000 after purchasing an additional 40,915 shares during the period. Franklin Resources Inc. increased its stake in Verve Therapeutics by 20.9% in the third quarter. Franklin Resources Inc. now owns 34,155 shares of the company's stock valued at $172,000 after purchasing an additional 5,914 shares during the period. GAMMA Investing LLC increased its stake in Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after purchasing an additional 3,964 shares during the period. Finally, Green Alpha Advisors LLC increased its stake in Verve Therapeutics by 15.0% in the fourth quarter. Green Alpha Advisors LLC now owns 29,438 shares of the company's stock valued at $166,000 after purchasing an additional 3,840 shares during the period. 97.11% of the stock is owned by institutional investors and hedge funds.

Verve Therapeutics Stock Performance

Shares of VERV opened at $5.76 on Monday. The company has a market capitalization of $511.46 million, a price-to-earnings ratio of -2.34 and a beta of 1.86. Verve Therapeutics, Inc. has a 1 year low of $2.86 and a 1 year high of $9.31. The company's 50 day simple moving average is $5.34 and its 200 day simple moving average is $5.95.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Equities analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on VERV. Guggenheim lifted their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Royal Bank of Canada dropped their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Finally, HC Wainwright upped their target price on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, April 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $25.75.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.

Want to see what other hedge funds are holding VERV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.